Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to -$0.01.

  • Guided Therapeutics' EPS (Basic) changed 0.0% to -$0.01 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.05, marking a year-over-year decrease of 6666.67%. This contributed to the annual value of -$0.05 for FY2024, which is 3853.48% up from last year.
  • As of Q3 2025, Guided Therapeutics' EPS (Basic) stood at -$0.01, which was down 0.0% from -$0.01 recorded in Q2 2025.
  • In the past 5 years, Guided Therapeutics' EPS (Basic) registered a high of -$0.0 during Q3 2021, and its lowest value of -$0.09 during Q2 2021.
  • In the last 5 years, Guided Therapeutics' EPS (Basic) had a median value of -$0.01 in 2024 and averaged -$0.03.
  • Its EPS (Basic) has fluctuated over the past 5 years, first soared by 8421.05% in 2021, then plummeted by 68923.53% in 2022.
  • Quarter analysis of 5 years shows Guided Therapeutics' EPS (Basic) stood at -$0.04 in 2021, then crashed by 50.14% to -$0.06 in 2022, then surged by 83.94% to -$0.01 in 2023, then tumbled by 33.09% to -$0.01 in 2024, then rose by 18.09% to -$0.01 in 2025.
  • Its EPS (Basic) stands at -$0.01 for Q3 2025, versus -$0.01 for Q2 2025 and -$0.01 for Q1 2025.